Deadline Alert: MoonLake Immunotherapeutics (MLTX) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

Core Viewpoint - MoonLake Immunotherapeutics faces a class action lawsuit following disappointing Phase 3 trial results for its drug candidate sonelokimab, which failed to demonstrate efficacy compared to a competitor's product, leading to a significant drop in stock price [2][3]. Company Overview - MoonLake Immunotherapeutics is a biopharmaceutical company focused on developing innovative therapies, particularly in the field of immunotherapy [1]. Legal Proceedings - A class action lawsuit has been filed against MoonLake Immunotherapeutics, with a deadline of December 15, 2025, for shareholders to file a lead plaintiff motion [1][4]. - The lawsuit alleges that the company made materially false and misleading statements regarding its drug candidate sonelokimab and failed to disclose critical information about its efficacy compared to competitors [3]. Financial Impact - Following the announcement of the Phase 3 trial results on September 28, 2025, MoonLake's stock plummeted by $55.74, or 89.9%, closing at $6.24 per share on September 29, 2025, significantly harming investors [2].